Literature DB >> 16840777

Sequential proteolytic processing of the capsular Caf1 antigen of Yersinia pestis for major histocompatibility complex class II-restricted presentation to T lymphocytes.

Julie A Musson1, Margaret Morton, Nicola Walker, Helen M Harper, Hesta V McNeill, E Diane Williamson, John H Robinson.   

Abstract

We studied the mechanisms of antigen presentation of CD4 T cell epitopes of the capsular Caf1 antigen of Yersinia pestis using murine bone marrow macrophages as antigen presenting cells and T cell hybridomas specific for major histocompatibility complex (MHC) class II-restricted epitopes distributed throughout the Caf1 sequence. The data revealed diversity in the pathways used and the degrees of antigen processing required depending on the structural context of epitopes within the Caf1 molecule. Two epitopes in the carboxyl-terminal globular domain were presented by newly synthesized MHC class II after low pH-dependent lysosomal processing, whereas an epitope located in a flexible amino-terminal strand was presented by mature MHC class II independent of low pH and with no detectable requirement for proteolytic processing. A fourth epitope located between the two regions of Caf1 showed intermediate behavior. The data are consistent with progressive unfolding and cleavage of rCaf1 from the amino terminus as it traverses the endosomal pathway, the availability of epitopes determining which pool of MHC class II is preferentially loaded. The Caf1 capsular protein is a component of second generation plague vaccines and an understanding of the mechanisms and pathways of MHC class II-restricted presentation of multiple epitopes from this candidate vaccine antigen should inform the choice of delivery systems and adjuvants that target vaccines successfully to appropriate intracellular locations to induce protective immune responses against as wide a T cell repertoire as possible.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16840777     DOI: 10.1074/jbc.M605482200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  Presentation of the candidate rheumatoid arthritis autoantigen aggrecan by antigen-specific B cells induces enhanced CD4(+) T helper type 1 subset differentiation.

Authors:  Caroline L Wilson; Dominic W Hine; Ariel Pradipta; Jeffrey P Pearson; Willem van Eden; John H Robinson; Andrew M Knight
Journal:  Immunology       Date:  2012-04       Impact factor: 7.397

2.  Mechanisms of major histocompatibility complex class II-restricted processing and presentation of the V antigen of Yersinia pestis.

Authors:  Ho-Ki Shim; Julie A Musson; Helen M Harper; Hesta V McNeill; Nicola Walker; Helen Flick-Smith; Alexei von Delwig; E Diane Williamson; John H Robinson
Journal:  Immunology       Date:  2006-08-18       Impact factor: 7.397

3.  A vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challenge.

Authors:  Sukumar Pal; Olga V Tatarenkova; Luis M de la Maza
Journal:  Immunology       Date:  2015-10-01       Impact factor: 7.397

4.  Immunogenicity of a Yersinia pestis vaccine antigen monomerized by circular permutation.

Authors:  David A Chalton; Julie A Musson; Helen Flick-Smith; Nicola Walker; Alistair McGregor; Heather K Lamb; E Diane Williamson; Julie Miller; John H Robinson; Jeremy H Lakey
Journal:  Infect Immun       Date:  2006-09-18       Impact factor: 3.441

5.  Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccine.

Authors:  Delia F Tifrea; Guifeng Sun; Sukumar Pal; Gustavo Zardeneta; Melanie J Cocco; Jean-Luc Popot; Luis M de la Maza
Journal:  Vaccine       Date:  2011-05-06       Impact factor: 3.641

6.  Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.

Authors:  Delia F Tifrea; Sukumar Pal; Jean-Luc Popot; Melanie J Cocco; Luis M de la Maza
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

7.  Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein.

Authors:  Guifeng Sun; Sukumar Pal; Joseph Weiland; Ellena M Peterson; Luis M de la Maza
Journal:  Vaccine       Date:  2009-05-27       Impact factor: 3.641

Review 8.  Protecting against plague: towards a next-generation vaccine.

Authors:  E D Williamson; P C F Oyston
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

9.  Vaccination with the recombinant major outer membrane protein elicits antibodies to the constant domains and induces cross-serovar protection against intranasal challenge with Chlamydia trachomatis.

Authors:  Delia F Tifrea; Pooja Ralli-Jain; Sukumar Pal; Luis M de la Maza
Journal:  Infect Immun       Date:  2013-03-11       Impact factor: 3.441

Review 10.  Thymus-specific serine protease, a protease that shapes the CD4 T cell repertoire.

Authors:  Sylvie Guerder; Chervin Hassel; Alice Carrier
Journal:  Immunogenetics       Date:  2018-09-17       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.